Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Staging soft tissue sarcoma: evolution and change.

Dhanasekaran Kotilingam1, Dina Chelouche Lev, Alexander J F Lazar

  • 1The University of TexasMD Anderson Cancer Center, Houston, TX, USA.

CA: a Cancer Journal for Clinicians
|September 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Variability in Extracellular Vesicle Characterization Across Measurement Techniques.

Journal of extracellular biology·2026
Same author

Notch signaling regulates the secretion of pro-metastatic factors in extracellular vesicles in liposarcoma.

Cancer letters·2026
Same author

Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing.

PloS one·2025
Same author

Oncogenic Functions of Alternatively Spliced <i>MDM2-ALT2</i> Isoform in Retroperitoneal Liposarcoma.

International journal of molecular sciences·2025
Same author

Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research.

Oncology research·2024
Same author

Targeted transcriptomic analysis of well-differentiated and dedifferentiated liposarcoma reveals multiple dysregulated pathways including glucose metabolism, TGF-β, and HIF-1 signaling.

Frontiers in oncology·2024
Same journal

Serious mental illness and cancer: A call to action for equitable care.

CA: a cancer journal for clinicians·2026
Same journal

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same journal

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

CA: a cancer journal for clinicians·2026
Same journal

Study finds ovarian cancer survivors who are BRCA carriers have a relatively low risk of breast cancer.

CA: a cancer journal for clinicians·2026
Same journal

Radiation therapy, cytogenetic prognostication, novel systemic chemotherapy, and patient perspective in an adult with choroidal melanoma.

CA: a cancer journal for clinicians·2026
Same journal

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

CA: a cancer journal for clinicians·2026
See all related articles

Soft tissue sarcoma (STS) is a rare, heterogeneous cancer originating from mesenchymal cells. Current AJCC staging aids prognosis and treatment, with future improvements anticipated from molecular insights.

Area of Science:

  • Oncology
  • Pathology
  • Medical Diagnostics

Background:

  • Soft tissue sarcoma (STS) represents a rare and highly diverse group of tumors with a mesenchymal cell origin.
  • STS commonly metastasizes hematogenously, with the lungs being a primary site.
  • Accurate staging is crucial for predicting prognosis and guiding treatment strategies.

Purpose of the Study:

  • To evaluate the utility of the current American Joint Committee on Cancer (AJCC) staging system for soft tissue sarcoma.
  • To identify areas for improvement in STS staging.
  • To anticipate future advancements in STS classification.

Main Methods:

  • Review and analysis of the current AJCC staging criteria for STS.
  • Inclusion of Tumor, Grade, Node, and Metastasis (TNM) components.

Related Experiment Videos

  • Consideration of superficial ('a') and deep ('b') designations.

    • Main Results:

    • The current AJCC staging system provides valuable prognostic information for STS.
    • The system incorporates key factors like tumor characteristics, grade, nodal status, and metastasis.
    • Superficial and deep tumor designations are part of the current staging framework.

    Conclusions:

    • The existing AJCC staging for STS is instrumental in prognosis and treatment planning.
    • Opportunities exist to enhance the staging system, particularly with emerging molecular data.
    • Future iterations of STS staging are expected to be more refined and informative.